Leerink Partnrs Analysts Reduce Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Equities researchers at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Edwards Lifesciences in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings per share of $0.58 for the quarter, down from their previous estimate of $0.60. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' Q2 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.63 EPS, FY2028 earnings at $3.70 EPS and FY2029 earnings at $4.18 EPS.

EW has been the subject of a number of other reports. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Down 0.7 %

NYSE EW traded down $0.52 during trading hours on Friday, reaching $75.67. 4,937,936 shares of the company's stock traded hands, compared to its average volume of 4,574,817. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market cap of $44.63 billion, a PE ratio of 10.92, a PEG ratio of 3.64 and a beta of 1.10. The firm has a 50-day simple moving average of $72.78 and a 200 day simple moving average of $69.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EW. Alpha Financial Partners LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $693,000. Vontobel Holding Ltd. lifted its stake in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company's stock valued at $28,977,000 after buying an additional 23,560 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $792,000. Trust Co. of Vermont lifted its stake in shares of Edwards Lifesciences by 36.1% during the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company's stock valued at $199,000 after buying an additional 801 shares in the last quarter. Finally, V Square Quantitative Management LLC lifted its stake in shares of Edwards Lifesciences by 10.6% during the 3rd quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company's stock valued at $992,000 after buying an additional 1,437 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 over the last three months. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.